We present a relatively simple, abstract, yet mechanistically realistic, in silico intestinal device (ISID). Its design enabled exploration of the mechanistic details of absorption for passively absorbed compounds that are also dual substrates of drug-metabolizing enzymes (CYP) and transporters (PGP), including P-glycoprotein. CYP and PGP, functioning as validated analogs of their referents, are autonomous software objects within the ISID. These and other autonomous objects were plugged together to form a device, an ISID, that represents intestinal features at different scales and levels of detail. Changes in proximal-to-distal levels of CYP and PGP are represented separately from the mechanisms that influence drug absorption and metabolism. Results for six proximal-to-distal CYP-PGP patterns are presented, along with results for different CYP/PGP ratios and amounts. We detected no CYP-PGP synergy. However, CYP-PGP antagonism was measured. Increasing the PGP/CYP ratio to 10 increased compound retention in the simulated lumen but did not increase total metabolism. Different proximal-to-distal CYP-PGP patterns, with and without simulated nonspecific, intracellular binding, had substantial effects on measures of absorption, metabolism, and metabolic extraction ratio within the ISID. The changes were due more to CYP than to PGP. The ISID represents a new class of models that is suitable for experimentation. It expands the repertoire of experimental methods for unraveling the mechanistic details of intestinal drug absorption and in anticipating the absorption consequences of drug interactions. To distinguish clearly in silico compounds and processes from corresponding intestinal structures and processes, we use small caps when referring to the former.
How can we unravel the complexities of intestinal absorption sufficiently to anticipate, with acceptable accuracy, the absorption of a compound that is subject to metabolism and active or facilitated transport? It becomes problematic when both processes are involved (Mouly and Paine, 2003; Cao et al., 2006; Dokoumetzidis et al., 2007) because there can be heterogeneity and individual differences in the levels and expression patterns of transporters and metabolic enzymes along the length of the intestine (Paine et al., 1997; Zhang et al., 1999; Mouly and Paine, 2003) . Differences in intestinal transit and other factors further increase the system's complexity (Kimura and Higaki, 2002) . P-glycoprotein (Pgp) and the drug-metabolizing enzyme CYP3A4 are most important in limiting intestinal absorption (Watkins, 1997; Wacher et al., 1998) . Although Pgp and CYP3A4 play separate roles in restricting absorption, it is believed that they can function synergistically to increase intestinal metabolism (Gan et al., 1996; Watkins, 1997; Wacher et al., 1998; Ito et al., 1999) . The idea has been that efflux would increase intestinal drug residence time and that would enable more exposure to and thus more extensive metabolism by CYP3A4. Accordingly, Kivistö et al. (2004) and others (Cummins et al., 2002 (Cummins et al., , 2003 have called for methods to achieve greater insight into the joint actions of Pgp and CYP3A4. As Cummins et al. (2002 Cummins et al. ( , 2003 have demonstrated, it has been challenging to selectively reduce the complexity of experimental wet lab systems because interventions, such as administration of a transport inhibitor, can alter mechanisms and create new uncertainties. With such complex systems, there can exist several different, plausible mechanistic explanations for experimental observations. In such cases, it can be challenging to identify the most likely explanation. Experimentation with mechanistically realistic, in silico analogs provides a new method that can supplement wet lab options for achieving deeper insight.
The recently introduced synthetic modeling method (Grant et al., 2006; Hunt et al., 2006; Garmire et al., 2007; Tang et al., 2007; Yan et al., 2007) is intended specifically to engineer models that can be useful for gaining mechanistic insight into complex biological phenomena such as intestinal absorption of compounds that are substrates for both Pgp and CYP3A4. Such models can be constructed consistent with current knowledge using validated components. They are advanced examples of what has recently been called executable biology (Fisher and Henzinger, 2007) . When simulation results mimic targeted behaviors, intestinal absorption in this case, the models can be used as objects of experimentation to explore answers to mechanistic questions that would be difficult, impossible, or unethical to answer using biological systems. Following iterative validation, the expectation has been that these models will become useful in anticipating intestinal absorption in advance of costly wet lab experiments. In this report, we present an abstract, yet mechanistically realistic, physiologically based, intestinal analog. The amounts, ratios, and locations of analogs of Pgp and drug-metabolizing enzymes (called PGP and CYP) along the length of the simulated intestine can be easily manipulated. We refer to these assembled systems as in silico intestinal devices (ISIDs) .
We explored the impact on simulated passive absorption of compounds that are dual substrates of CYP and PGP. Results for six different proximal-to-distal CYP-PGP patterns are presented, along with results for different CYP/PGP ratios and absolute amounts. The locations and fates of compounds within the ISID were followed to determine the consequences of CYP-PGP interactions. Contrary to expectations, no CYP-PGP synergy was measured. Interestingly, the conditions studied (CYP and PGP having similar levels and substrate reactivates) gave rise to a small but significant degree of CYP-PGP antagonism. Increasing the PGP/CYP ratio from about 1 to 10 increased compound retention in the simulated intestinal lumen, which caused more compounds to exit the intestine but decreased, rather than increased, total metabolism. Different proximal-to-distal CYP-PGP patterns had substantial effects on measures of simulated absorption, metabolism, and extraction ratio. The changes were due more to CYP than to PGP; a pattern of decreasing proximal-to-distal CYP, for fixed amounts of PGP and CYP, dramatically increased metabolism and extraction ratios. We submit that these simulation results may have in vivo counterparts.
This study demonstrates that for this relatively simple, abstract, but mechanistically realistic ISID, the consequences of interventions, such as changing CYP patterns relative to those of PGP, can be nonintuitive initially. Having methods such as those presented to explore scenarios and plausible, mechanistic explanations, in whatever detail is needed, will help achieve deeper insight into the biological mechanisms. The ISID and the results presented expand the repertoire of experimental methods for unraveling the mechanistic details of intestinal drug absorption and in anticipating the absorption consequences of drug interactions.
Materials and Methods
To distinguish clearly in silico compounds and processes from corresponding intestinal structures and processes, we use small caps when referring to the former.
Model Structures and Components. The componentized structure of the ISID is illustrated in Fig. 1 . It is a straightforward application of the already validated in silico transwell device (ISTD) (Garmire et al., 2007) . It is an example of the synthetic modeling method . The ISID is an abstract, physiologically based representation of an arbitrary length of small intestine in which the intestinal wall is represented as a monolayer of epithelial cells. It is not intended to duplicate the intestine, detail-for-detail. All ISTD components and spaces were reused here, with only the changes noted below. For convenience, an abridged description of ISTD methods follows. For additional detail, consult (Garmire et al., 2007) .
To create the ISID, four of the five parallel, square, ISTD spaces, S2 to S5, were simply rolled around S1, in the form of a series of concentric cylinders, so that two parallel edges of each space joined. The same approach was used to create the sinusoidal segments used in the in silico liver . S1 represents cylindrical intestinal luminal contents, with a radius of about 1.5 cm (Stubbs et al., 1998) . S1-4 map to an epithelial monolayer, S2 maps to apical membranes, S3 corresponds to intracellular spaces, and S4 represents basolateral membranes. S5 maps to capillary blood. Each S2 to S5 space was discretized further using a two-dimensional rectangular grid containing m by n elements; the dimension m maps to the circumference of the inner intestinal wall (3 cm). The dimension n maps to the length of the small intestine (5 M) (Lin et al., 1999) . The m and n values control the lower limit of spatial resolution and the precision of simulated behaviors. In this report, m ϭ 75 and n ϭ 4000.
The volumetric nature of elements in S1-4 is simulated by placing at each grid location a software object that acts as a container having an arbitrary but specifiable CAPACITY (a virtual volume). The effective CAPACITY of each element in S1-4 is given by a relative (with respect to radius) "height" parameter (H). For S1, H is the radius of the simulated intestinal luminal content, 1.5 cm. As discussed by Garmire et al. (2007) , H for S1-4 corresponds to the typical height of the referent space in an epithelial cell monolayer. The values used are listed in Table 1 . Each element is also labeled with relevant chemical properties, such as pH (in silico pH); in this report, S1-4 pH ϭ 7.4. Tight junctions are as detailed by Garmire et al. (2007) . They occupy 0.066% of S1-4 elements. A COMPOUND (also called a DRUG) is a mobile object. A stationary agent called PGP (also called TRANSPORTER) maps to a portion of all transporters that can transport drugs. A stationary agent called CYP (also called ENZYME) maps to a portion of all metabolic enzymes that can metabolize drugs. Both are discussed further below.
During the formative project stage, it was not clear how much detail should be represented. For a given systemic phenomena, some system details are simply irrelevant. When it was unclear that a detail would be needed, we used exploratory simulation to determine when that detail would be needed. For example, we can combine collocated elements of S2, S3, and S4 and have them function as a unit that maps to a collection of intestinal epithelial cells. For the specified ISID uses, is such detail needed? We conducted exploratory experiments (data not shown) in which S2 to S4 spaces were subdivided into isolated segments; a compound within a segment of S3, for example, could not move FIG. 1. The ISID and its components. A, four concentric spaces, S2 to S5, each represented by a two-dimensional grid, surround a cylindrical core (S1) that represents intestinal lumen content. S5 represents blood. The intestinal wall is simulated as a monolayer of epithelial cells. S2 and S4 represent the apical and basolateral cell membranes, respectively. S3 represents intracellular content. Arrow, proximal-todistal LUMINAL flow. B, container objects are placed on the elements of the S1 to S4 grids. This insert shows their relative sizes; two elements in each space are shown. C, dose of COMPOUND in a simulated volume is introduced into the proximal end of S1 using an impermeable conductor. D, objects representing metabolizing enzymes (CYP) and apical drug transporters (PGP) occupy a subset of S3 and S2 elements, respectively. During a simulation, each one searches a local neighborhood, shown shaded, for a COMPOUND with which to interact. directly into an adjacent segment of S3 without first exiting to S1 and then entering the adjacent segment through S2. Because of the effective thinness of S1-4, we found that neither course nor fine-grained segmentation influenced systemic ISID measures. Consequently, it was not used, but it can be added easily should it be needed by descendants of these ISIDs.
We added a conductor component (insert, Fig. 1 ) at the proximal end of S1. It has no biological counterpart. Rather, it holds and delivers the dose of COMPOUNDs to simulate dissolved drug in a volume of fluid arriving from higher in the gastrointestinal tract. The conductor has the same radius as S1. Its length was optimized to avoid any artifacts that may arise from too many COMPOUNDs entering the ISID too quickly and to minimize the lag-time effect that would result from too few COMPOUNDs entering too slowly. Except when noted otherwise, simulations were initiated with 1000 COMPOUNDs. One set of experiments used dose ϭ 2000 COMPOUNDs to provided insight into the effects of changes in dosed amounts.
Passive Dispersion and Biased Flow in S1. Passive dispersion of COM-POUND in all directions, as described by Garmire et al. (2007) , occurs in S1 to S4, whereas biased dispersion only occurs in S1 to simulate flow of intestinal contents (objects in S1 were subject to both passive dispersion and biased forward movement, as stated in the equation below). Passive dispersion involves transition between and within spaces and relocation within an element. We introduced two modifications of those movement mechanisms. 1) Once a COMPOUND appears in S5, it stays there; random movement back to S4 is not allowed. With that restriction, we mimic the "sink condition" that is usually assumed for drug entering blood from the intestine (Ingels and Augustijns, 2003) . 2) In S1, we simulate flow as follows. Every COMPOUND used a rule to schedule a transition opportunity at some future time, t t ; for COMPOUNDs within S1 and S3 of the ISTD (Garmire et al., 2007) , that time was calculated using Einstein's one-dimensional diffusion function: t t ϭ t c ϩ (H Ϫ h 0 ) 2 /2D. t c is the current simulation time, H is the relative "height" of elements within the space in which the COMPOUND resides (Table 1) , D is the diffusion coefficient in that space (it was calculated as specified in the appendix of Garmire et al., 2007) , and h 0 is the COMPOUND's current location within that element. In S2, h 0 ϭ 0 at the S1 to S2 interface, and so on. In S1, the parameter h 0 is the distance of a COMPOUND from the cylinder's axis. If h 0 ϭ 0, the COMPOUND is at the S1 axis, and if h 0 ϭ H 1 , the COMPOUND is located at the interface of S1 and S2. A COMPOUND's movement in S1 of the ISID is comprised of radial movement combined with simulated flow relative to the cylinder's surface. The cylinder's width is 2h 0 , and its length is n ϭ 4000 as above. At t t , the COMPOUND calculated a new location for itself (Garmire et al., 2007) . Briefly, in each simulation cycle, a new position (x t , y t ) within the same space and within a fixed update interval of t ϭ ⌬5 s is calculated as x t ϭ x 0 ϩ ͌(4D⌬t)(rv ϫ sin) and y t ϭ y 0 ϩ ͌(4D⌬t)(rv ϫ cos ϩ e); (x 0 , y 0 ) is the center of the element in which a COMPOUND is located, rv is a random value drawn from a standard Gaussian distribution (mean ϭ 0, S.D. ϭ 1), is an angle drawn from the uniform distribution on (0, 2), and D is the referent compound's diffusion coefficient in the referent space. e is a bias factor added to the random walk to simulate proximal-to-distal flow along S1. When x t is larger than 2h 0 , the COMPOUND's destination on the circumference is determined by (x t Ϫ 2Nh 0 ); N is the integer that makes 0 Յ (x t Ϫ 2Nh 0 ) Ͻ 2. A COMPOUND is eliminated from the ISID when y t Ͼ N. In this report, we used two values of D in S3: 1.69 ϫ 10 Ϫ6 and 1.69 ϫ 10 Ϫ8 cm 2 /s. These D values were selected so to be comparable with those used by Ito et al. (1999) .
Effects of CYP and PGP. Already validated ENZYME objects (Garmire et al., 2007) were reused here. Briefly, the enzymatic reaction algorithm is a stochastic analog of the conventional kinetic model. When scheduled, each CYP agent updates its state depending on its internal logic, the nature of, and relative location of objects in its local environment, and values drawn from a pseudorandom number generator. A CYP has two substrate-binding sites, so that self-activation and/or self-inhibition can be simulated. In this report, for simplicity, we inactivated the second site of the ENZYME objects that were validated by Garmire et al. (2007) . By so doing, the ENZYME had only one active site, and as documented by Garmire et al. (2007) , its metabolic properties exhibited simple Michaelis-Menten kinetics. A CYP is in one of the two Simulated S1 and S5 pH 7.4
a One ISID length-width unit maps to 0.125 cm. b Seventy-five width units map to the circumferences (3 cm) of human small intestines, calculated from the small intestinal diameter of 3.0 cm (Stubbs et al., 1998) . c Four thousand length units map to the 5-m length of a human small intestine (Lin et al., 1999) . d Values were optimized from Garmire et al. (2007) . e One unit of S1-4 element height maps to a typical membrane thickness of 7.5 to 10 nm (Garmire et al., 2007) . f According to Stubbs et al. (1998) , 1.5 ϫ 10 6 units of element height maps to a lumen radius of 1.5 cm. g According to Freitas (1999) , 2.0 ϫ 10 3 units of element height maps to the 20-m thickness of epithelial cells.
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states: with or without a bound COMPOUND. State changes can occur within each 0.5-s simulation cycle. Each free CYP scans the 24 elements comprising its local neighborhood (illustrated in Fig. 1 ) and selects the COMPOUND within that has the smallest assigned pseudorandom number. If that number is less than the CYP-COMPOUND binding probability, P 1 , it binds the COMPOUND. Otherwise, it ignores any COMPOUND and waits until the next opportunity. When a CYP has a bound SUBSTRATE, it decides whether to release it as a METABOLITE. The decision is based on the relationship between a new pseudorandom number and P 2 ; if that pseudorandom number is less than P 2 , a METABOLITE is released. Otherwise, the CYP-COMPOUND complex will be unchanged at the start of the next simulation cycle. For simplicity, we specified that METABOLITEs inherit the physicochemical properties (PCPs) of COMPOUNDs, including the COMPOUND's CYP and PGP binding affinities and releasing probabilities listed in Table 1 . The CYP agent and its mechanism, which were detailed by Garmire et al. (2007) , were general and designed to be reused for other purposes. By simply changing the logic and/or location, it can serve as an analog to some other cell component such as a transporter. The PGP agents are slightly modified versions of CYP. Only one site was used, a one-site PGP that had been validated earlier against data from in vitro model (Sheikh-Bahaei and Hunt, 2006) . The logic used by each PGP to deal with objects in its S3 neighborhood is the same as that used by CYP. Once a COMPOUND or METABOLITE is bound, the complex moves to the S2-S1 interface, and the object is released into S1 randomly along the radius of the ISID. When facing S1, PGP is inactive. After releasing an object, it moves back to its original location facing S3. In that state, it is again active.
For each 0.5-s simulation cycle, extraction ratio (ER) measured the fraction of COMPOUND that was actually METABOLIZED among what was available for METABOLISM during the last simulation cycle:
In general, the density of Pgp-type transporters increases from the jejunum to the ileum, whereas the density of drug-metabolizing enzymes decreases from the jejunum to the ileum (Mouly and Paine, 2003; Paine et al., 1997) . Along the small intestine, their gene expression levels are comparable (Cao et al., 2006) . To represent their relative densities, we subdivided the ISID into eight segments and randomly placed different amounts of CYP and PGP within each segment as specified in Table 2 . Choice of the total amount of CYP and PGP was somewhat arbitrary but was guided by four constraints: 1) DOSE/total(CYP ϩ PGP) Յ 1; 2) the relative, separate trends of CYP and PGP along the eight segments in Table 2 should closely match the listed, relative gene expression levels; 3) we did not want CYP/PGP in any one segment to deviate too far from 1.0; we arbitrarily specified 0.5 Ͻ CYP/PGP Ͻ 2 within any one of the eight segments; and 4) we wanted CYP(total)/PGP (total) to be close to 1.0; we arbitrarily specified 0.8 Յ (total CYP)/(total PGP) Յ 1.2. Specifying CYP ϭ 480 and PGP ϭ 419 met those constraints, so those amounts were used for most experiments.
Discrete Event Schedule. The ISID used discrete event simulation. Simulations are advanced by dynamically scheduling events at realistic times. Two levels of agents manage event scheduling. Each scheduling agent implements heap tree (a priority queue) data structures to ensure fast event insertion, rescheduling, and deletion (Cormen et al., 1990 Software. The ISID is built from Swarm platform and libraries (http:// swarm.org). We coded in Java Swarm. Doing so gave direct access to Swarm's Objective-C libraries and enabled the created software to be easily integrated with R and MATLAB version 13 (Mathworks Inc., Natick, MA). Most experiments were executed on an eight node OSCAR cluster (http://oscar. openclustergroup.org) running RedHat's Fedora 5. The distribution of the runs used MPICH 1.2.7 (http://www-unix.mcs.anl.gov/mpi/mpich1). The initial pseudorandom number seed was extracted from the machine's clock. The input data were fed automatically from the MATLAB script for sequential runs, in which an interface was linked with Java Swarm. The output data files, in Java Swarm, were automatically linked and processed using MATLAB and R. We conducted parameter tuning, graphing, data analysis, and data fitting in MATLAB version 13. We repeated most simulations 10 to 15 times; results are reported as arithmetical mean values, unless otherwise noted. We assumed that the central limit theorem holds for all observations.
Results
Simulating ISID Input and Flow. Drug in solution enters the small intestine from the stomach. We simulated that process. Placing all COMPOUND in the most proximal element of S1 at t ϭ 0 caused unrealistic, rapid transport during the first few simulation cycles. Curve 1 in Fig. 2A shows the effect. If the amount entering that element from upstream was too small, there was, on average, a lag time before any transport was detected in S5. Having a nonpermeable, adjustable conductor attached to the proximal end of S1 allowed us to select dosing options between those extremes. Several sizes were tested (different lengths, in elements, containing different numbers of simulated milliliters). Results from using 10 of those conductor configurations are shown in Fig. 2 . The test COMPOUND (its selection is described below) used for these studies represented a hypothetical basic compound, having mol wt. ϭ 500 and logP ϭ 3. The conductor having a length of three elements and a volume of 3 simulated ml was selected and used for all subsequent experiments.
Movement of COMPOUND within and between elements in S1-4 is random (Garmire et al., 2007) . The simplest way to simulate proximal-distal flow in S1, the method used, is to instruct each object to move farther than it would using a simple random walk whenever a move toward the distal end of S1 is scheduled. This was done by adding an additional unitless biased walk parameter e; in Materials and Methods, it is called the biasFactor. The mean transit time through human small intestines for the 400 drugs (Yu et al., 1996) was approximately 199 min. We wanted the ISID to exhibit simulated mean transit times that were similar. Following the lead of Kalampokis et al. (1999) , we made S2 impermeable to confine the dose to S1. We then explored the consequences of using different biasFactor values. Results from five of these experiments are shown in Fig. 3 . When using a biasFactor of 50, 50% COMPOUNDs had exited after 199 min. Inspection of the insert in Fig. 3A also shows that the simulated maximum elimination rate for biasFactor ϭ 50 fell between about During those biasFactor experiments, we monitored the amount of COMPOUND in each of the 4000 S1 elements from the proximal to the distal end. We pooled data from a sequence of 20 equally distant segments along the proximal to distal ISID. Results are summarized in Fig. 3B for biasFactor ϭ 50. The approximate Gaussian shape of the histogram profiles along with their increasing variance with increasing simulated time is consistent with dispersion occurring during flow through a tube.
Effects of PGP and CYP on Simulated Absorption and Metabolism. We provided validation experiments for two-site, enzyme-substrate reaction mechanisms in the previous report (Garmire et al., 2007) . For this report, we inactivated the second substrate-binding site. The result was a CYP object that exhibited simple MichaelisMenten kinetics. A copy of that object was modified to represent PGP. Rather than releasing a METABOLITE, a PGP released the original COM-POUND. Before combining and experimenting with the CYP and PGP within the same ISID, we verified the function of each within the ISID using different values of P 1 and P 2 (Table 1) and two different levels of PGP. To simplify comparisons, exploratory simulations, identical to those in Garmire et al. (2007) , were conducted to select a reference COMPOUND that would, at the conclusion of the experiment, exhibit similar values of: 1) ABSORPTION (accumulation in S5), 2) the amount of COMPOUNDs exiting the ISID from S1, and 3) LUMEN retention. A basic COMPOUND having mol wt. ϭ 500, logP ϭ 3 was selected. All experiments used 480 CYPs distributed along the ISID using the pattern specified in Table 2 . One set of experiments used 419 PGPs distributed along the ISID as specified in Table 2 , and another used 4190 distributed identically. Ten repetitions were completed for each experiment condition. The control condition, which had P 1 ϭ 0 for both CYP and PGP, simulated passive absorption; it also simulated complete inhibition of both CYP and PGP. The results are shown in Fig. 4 .
When the 419 PGPs were active (i.e., P 1 and P 2 ϭ 0.5 or 1), ABSORPTION decreased, and the amount of COMPOUNDs exiting from the distal end of S1 increased relative to control values. Contrary to expectations inferred from the literature (Hochman et al., 2000) , there was no significant change in LUMEN retention. However, for the experiments in which we used 4190 PGPs (Fig. 4A) , mean LUMEN retention increased from 301 to 379 COMPOUNDs. The mean amount that exited the distal end of S1 increased from 332 to 408 COMPOUNDs, whereas mean ABSORPTION decreased from 366 to 213, consistent with expectations.
Absent PGPs, activating the 480 CYPs caused about 10% of the dose to be metabolized on passing through S3 (Fig. 4B) , which was sufficient for the objectives of this study. By decreasing either P 1 or P 2 from 1 to 0.5, metabolism decreased significantly. There are several ways to increase simulated metabolism without altering specific ISID components or their arrangements. One is to increase the local neighborhood (Fig. 1D) surveyed by each CYP during each simulation cycle.
Different, Relative PGP and CYP Patterns Can Influence ABSORP-TION Dramatically. A plausible contributor to interindividual variability in oral drug bioavailability is differences in the proximal-todistal patterns of relative densities of metabolic enzymes and transporters. We conducted experiments using the five different proximal-to-distal patterns shown in Fig. 5A to explore that issue. Total   FIG. 2. Results of experiments to select a conductor parameterization. The conductor in Fig. 1C can be viewed as the upstream source of volume containing COMPOUNDs FLOWING into the proximal end of S1. Too many COMPOUNDs entering the first element of S1 creates a large gradient that results in unrealistic permeation values at early times. Too few COMPOUNDs entering S1 results in a lag time until COMPOUND levels are sufficient to cause detectable accumulation in S5. An acceptable conductor parameterization avoids these two extremes. Each trial used 1000 COMPOUNDs having mol wt. ϭ 500 and logP ϭ 3. The amount of COMPOUND accumulated in S5 was measured every minute. The results are the means of 10 trials. A, curves, from top to bottom, show results for conductor lengths of one to five elements. In each case, the dose is contained in a simulated volume of 3 ml. B, curves, from top to bottom, show results for simulated solution volumes from 5 to 1 ml. In each case, the conductor had a length of three elements.
FIG. 3. Simulation of LUMINAL flow through S1
. A, to simulate flow, the random walk of each COMPOUND in S1 is biased in the distal direction, as described in the text. The graph shows the number of COMPOUNDs (dose ϭ 1000) remaining in S1 at the indicated time after dosing for biasFactor values ranging from ϭ 45 to 55; a value of 50 was used for all subsequent simulations. For these trials, S2 was impermeable; all COMPOUNDs were confined within S1. The insert shows the rate of COMPOUNDs exiting the distal end of S1 at the indicated times after dosing for biasFactor ϭ 50. Although the pattern of exiting S1 remains the same, the actual exit rates differed for each simulation. B, fraction of COMPOUNDs for the experiment in A in each of 20, equal-length segments along the ISID at five different times after dosing.
objects within the ISID in each case were the same: CYP ϭ 480 and PGP ϭ 419. We focused on observing the maximum differences among patterns by setting P 1 ϭ P 2 ϭ 1 for both CYP and PGP. We conducted 15 repeat experiments for each case. The results in Fig. 5 are arithmetic means.
In all cases, the amount ABSORBED increased until about 200 min, which is the mean transit time of the simulation; thereafter, on average, no significant additional absorption occurred. The different proximal-to-distal CYP and PGP patterns caused only modest changes in amount absorbed (Fig, 5B) because passive ABSORPTION for the reference COMPOUND dominates. However, it was not surprising that relative differences in METABOLISM and extraction ratio (Fig. 6) showed clearly the influence of the different CYP and PGP patterns. The pattern for CYP dominates; switching the PGP pattern from a to b (or d to e) did not meaningfully change either cumulative METABOLISM (Fig. 6A) or extraction ratio profiles (Fig. 6B) . By 60 min, at least 50% of ABSORP-TION had occurred. The data document that having more CYP toward the proximal end of the ISID (cases a and b relative to case c) caused more METABOLISM. Prior to reaching an asymptote at about 200 min, cumulative METABOLITE profiles exhibit three CYP-dependent patterns (Fig. 6A) . When both CYP and LUMINAL COMPOUND levels declined proximal-to-distal (a and b), we observed early, rapid METABOLITE accumulation. When CYP levels increased proximal-to-distal (d and e), early METABOLISM was least. When CYP levels were constant (pattern c), the rate of METABOLITE accumulation decreased in parallel with declining LUMINAL COMPOUND levels.
For pattern c, where the proximal-to-distal ratio of PGP and CYP is constant, we saw that extraction ratio increased for about the first 25 min and then remained constant (Fig. 6B) . During the first 25 min, the rate of passive transport is largest. Because ER takes into account both METABOLISM and passive transport, a small amount of metabolism, together with a relatively large amount of COMPOUND undergoing passive transport, suppressed ER values. A similar but more pronounced rise in ER was seen for patterns a and b, but the trend stabilized for an interval and then began to decline reflecting the decline in CYP densities. That early trend was absent for patterns d and e because for both, CYP densities always increased downstream.
Relative PGP and CYP Expression Levels Influence ABSORPTION and METABOLISM. Another plausible contributor to variability in interindividual, oral bioavailability is the total, relative amount of metabolic enzymes and transporters within the intestine (Paine et al., 1997; Mouly and Paine, 2003) . To explore the consequences of such differences, we conducted four experiments in which PGP and CYP amounts were changed by a factor of 10, while maintaining the proximal-to-distal patterns specified in Table 2 . Results from 20 replicate experiments were averaged. Note that a 10-fold difference in PGP activity can result from different amounts or from a 10-fold inhibition of PGP in one ISID case relative to another. Below, for clarity, a change in CYP or PGP amount can also mean a change in activity. Experiments were conducted starting with a conductor that had length ϭ three elements containing 1000 COMPOUNDs (simulating a monoprotic, weak base; mol wt. ϭ 500, logP ϭ 3, pK a ϭ 7.4) in a simulated volume of 3 ml. Measurements were recorded 199 min after dosing. Results are shown as means Ϯ S.D.s for 10 repetitions. A, ISID had either 419 or 4190 PGPs assigned to elements in S2 according to the distribution specified in Table 2 . No CYPs were included in S3. P 1 is the probability of having a COMPOUND bound to a PGP within each 0.5-s simulation interval, and P 2 is the probability of having a bound COMPOUND released within that interval. Results are the amount of COMPOUND ABSORBED (transported to S5), the amount that exited the ISID, and the amount retained in S1 (LUMEN). ‫,ء‬ ABSORPTION is significantly less than that in the control, P 1 ϭ 0 (p Ͻ 0.05); ‫,ءء‬ efflux is significantly more than that in the control (p Ͻ 0.05). B, ISID had 480 CYPs assigned to elements in S2 according to the distribution pattern specified in Table 2 . No PGPs were included in S2. P 1 is the probability of having a COMPOUND bound to a CYP within each 0.5-s simulation interval, and P 2 is the probability of having a bound COMPOUND released within that interval. Right axis, total amount of METABOLITE formed. ‫,ء‬ ABSORPTION is significantly less than the control, P 1 ϭ 0 (p Ͻ 0.05); ‫,ءء‬ total METABOLITEs are significantly fewer than when P 1 ϭ P 2 ϭ 1 (p Ͻ 0 0.05). For both CYP levels, increasing PGP by 10-fold increased LUMEN retention of COMPOUNDs to about the same degree. It also increased almost the same degree of COMPOUNDs exiting the distal end of ISID (Fig. 7A) . Decreasing the amount of CYP 10-fold for the same amount of PGP caused ABSORPTION to increase. The magnitude of the effect was smaller when the amount of PGP was larger (Fig. 7B, gray curves) because in the latter case, more COMPOUNDs were exiting the distal end of the ISID (Fig. 7A) . The results were statistically indistinguishable when the dose was increased from 1000 to 2000 COMPOUNDs. Increasing PGP 10-fold for the same amount of CYP (changing CYP/PGP from 10:1 to 10:10 and from 1:1 to 1:10 in Fig. 8A ) decreased cumulative METABOLITE formation by about 50% for both the large and smaller amounts of CYP. However, increasing PGP 10-fold for the same amount of CYP did not dramatically alter measures of extraction ratio (Fig. 8B) , similar to the observations in Fig. 6B . When CYP levels were largest, having relatively more PGP caused slightly larger extraction ratio values. The effect was a consequence of how ER is defined; it is a measure of the fraction of COMPOUND that was available for METAB-OLISM and that was actually METABOLIZED. In these studies, PGP pumps both COMPOUNDs and METABOLITEs into the ISID LUMEN, increasing the amount of both that exits S1. The shape of the ER profile after about 25 min is a consequence of the changing ratio of CYP to PGP along the length of the ISID, as specified in Table 2 .
CYP-PGP Antagonism But Not Synergy Occurred. CYP-PGP synergy occurs when the decrease in ABSORPTION due to the combined function of CYP and PGP (relative to ABSORPTION in the absence of CYP and PGP) is greater than the sum of the separate effects: the reduced ABSORPTION when each is functioning alone. When CYP/PGP ϭ 480:419, no synergy occurred (data not shown); the results in Fig. 4 show that for that ratio, LUMEN levels of COMPOUNDs did not increase. We explored conditions that might be more conducive to synergy. Results of two conditions merit attention: CYP/PGP ϭ 480:4190, with and without simulated, nonspecific INTRACELLULAR (S3) binding of COMPOUNDs. Nonspecific binding can be represented is several ways. We present results for one of the simplest (also used by Ito et al., 1999) : decrease the COMPOUND's effective diffusion coefficient in S3. We decreased it 100-fold to 1.69 ϫ 10 Ϫ8 cm/s. Slowing INTRACELLULAR COMPOUND movement within a simulation cycle can map to multiple binding and release events in the referent. The simulation cycle was 0.5 s. The time between two, tandem-scheduled events for the same object (a CYP, PGP, or COMPOUND) was Ն0.5 s. Any event in the intestine that occurs within that interval is below the ISID's current level of simulation resolution.
The following experiments all used CYP/PGP ϭ 480:4190; for some experiments, both were active, for some other experiments, one or the other or both were deactivated. There were two sets of experiments for each of those four sets of conditions: with and without nonspecific binding. The results are means of 20 repeat experiments. When both CYP and PGP were active (P 1 ϭ 1 for both), the condition is designated CYP:PGP ϭ ϩ:ϩ; when either or both were deactivated by setting P 1 ϭ 0, it is designated CYP:PGP ϭ ϩ:-or -:-. The expected ABSORPTION, assuming no interaction, was calculated as specified under Materials and Methods. The time profiles of mean amounts ABSORBED are plotted in Fig. 9 . The box plots in Fig. 10 show results at 200 min; FIG. 6 . Effects of PGP and CYP gradients on METABOLISM and extraction ratio. The COMPOUND, dose, amounts and activities of CYP and PGP, and experiment conditions are the same as in Fig. 5 . The curves are labeled as in Fig. 5 . A, shown are mean, total METABOLITEs produced for each PGP and CYP pattern. Curves b and c are also included in Fig. 8A so that the metabolic consequences of these two PGP-CYP patterns can be compared with the metabolic consequences PGP-CYP pattern in Table 2 . B, corresponding values of extraction ratio, calculated every minute, are plotted versus simulated time.
FIG. 7. The effect of four different CYP and PGP levels on transport and LUMINAL retention. The ISID contained PGP and CYP arranged proximal-to-distal following the patterns listed in Table 2 . For convenience, CYP/PGP ϭ 480:419 is designated 1:1, and CYP/PGP ϭ 4800:4190 is designated 10:10. COMPOUND properties, dose, and experiment conditions are the same as in Fig. 4 . A, percent of dose retained in the LUMEN (S1) and that exited S1 are plotted versus time after dosing. B, time course of percent of dose ABSORBED, transported to blood (S5), is shown for each of the four CYP-to-PGP combinations. The dashed curves b and c are redrawn from Fig. 5B so that the absorption consequences of these two PGP-CYP patterns can be compared with the absorption consequences PGP-CYP pattern in Table 2 . ABSORPTION continues after 200 min, but the amount is only a few COMPOUNDs. The results were statistically indistinguishable when the dose was increased from 1000 to 2000 COMPOUNDs. they demonstrate the variability, built-in uncertainty, in these ISID experiments.
Inhibition of CYP increased ABSORPTION, as expected. The magnitude of the effect was increased with nonspecific binding (Fig. 9B) . Inhibition of PGP increased ABSORPTION more when nonspecific binding was absent, whereas the combined inhibition of CYP and PGP increased ABSORPTION more in the presence of nonspecific binding. The results in Fig. 9 and Table 3 show that no synergy occurred. As stated under Materials and Methods, METABOLITEs inherited all of the PCPs of the parent COMPOUND, including PGP P 1 and P 2 values. However, METABOLITEs had no affinity for CYP (P 1 ϭ 0).
Somewhat counterintuitively, the results showed a small but real degree of CYP-PGP antagonism (Figs. 9A and 10A; Table 3); the expected amount ABSORBED was less than measured ABSORPTION. The effect was enhanced with nonspecific binding within S3 (Figs. 9B and 10B; Table 3 ). Antagonism was a consequence of the density of COMPOUNDs being such that within one simulation cycle, a small fraction of COMPOUNDs was simultaneously in the local neighborhood of two or more binding objects, CYP and/or PGP. The probability of such an occurrence increased with increased COMPOUND densities caused by nonspecific binding. Because either CYP or PGP can bind a COMPOUND that is within their overlapping neighborhoods within a simulation cycle, the effectiveness of the loser (the one that, by chance, does not bind the target object) during that cycle is diminished.
The consequences of the events described above for dose ϭ 1000 on the time courses of LUMEN retention, formation of total METABOLITEs, and extraction ratio are presented in Fig. 11 . Nonspecific binding slightly increased LUMEN retention (Fig. 11A ), in part, because there was a higher probability that a COMPOUND would return to S1 from S3, both passively and by PGP transport. Nonspecific binding in S3 increased the probability for METABOLISM. Consequently, total METABOLISM and ER values (Fig. 11 , B and C) were increased. Consistent with the observations in Figs. 6 and 8, less METABOLISM but greater ER values were obtained when PGP was active.
Might the presence of active METABOLITEs (having an affinity for PGP) have obscured evidence of synergy? To explore the possibility, we repeated the preceding experiments, eliminating that affinity for PGP (P 1 ϭ 0); the results corresponding to the data in Fig. 11A were unchanged (data not shown). The results corresponding to the data in Fig. 9, A and B, after 100 min were also unchanged. Table 2 . Twenty repetitions were conducted; means are plotted. The designation CYP:PGP ϭ ϩ:Ϫ means that CYP was fully active (with P 1 ϭ P 2 ϭ 1), and PGP was inactive (with P 1 ϭ 0, simulating inhibition); Ϫ:ϩ means that CYP was inactive (with P 1 ϭ 0, simulating inhibition), and PGP was fully active (with P 1 ϭ P 2 ϭ 1); ϩ:ϩ means neither was inhibited, whereas Ϫ:Ϫ means that both were inhibited. A, amount ABSORBED is plotted versus time. The expected absorption absent any PGP-CYP interaction was calculated by summing observed absorption when only PGP is active, and when only CYP is active, and then subtracting the observed absorption when both PGPs and CYPs are active. B, experiments are the same as in A, except that nonspecific INTRACELLULAR binding was simulated by decreasing the COMPOUND's effective diffusion coefficient by a factor of 100. That new condition is designated by §. Garmire et al. (2007) validated the functionality of the components in Fig. 1 but in the absence of fluid flow. The data taken from those simulations were essentially indistinguishable from wet lab data (within the range of variability of wet lab experiments). Assume that within the ISID context, the simulated flow mechanism is a reasonable, low-resolution representation of intestinal flow. We submit that the relative relationships between ISID components, their logic, and how they are plugged together are similar to the corresponding component relationships within the intestine, from the perspective of measures of metabolism, luminal retention, and absorption. That degree of similarity provides ISID face validation for the current level of granularity and establishes a semiquantitative mapping between ISID and the intestine at the mechanism level: mapping C in Fig. 12 . ISID simulations are not intended to faithfully represent details occurring in the intestine during drug absorption. We claim only that similarities of form and function within the two systems, for the uses specified and from the perspective of the measurements taken, are sufficiently similar so that the ISID can be used as a surrogate of in situ intestinal absorption studies for the purposes of discovering plausible answers to mechanistic questions of the type addressed here.
Discussion
ISID mechanisms exist at the software execution level. They are easy to understand and follow. Recordable events occur during simulations from interactions of components and COMPOUNDs. To the extent that mapping C is mechanistically realistic, we can hypothesize that a second, semiquantitative mapping exists between events, such as CYP and PGP interactions or lack thereof, and corresponding events occurring within the intestine during absorption of a compound that is a dual CYP3A4 and Pgp substrate. Given mappings B and C, the expectation is that semiquantitative similarities will exist between measures of simulation events, such as ABSORPTION, METABOLISM, ER, and LUMINAL retention, and corresponding in situ and in vivo measures (mapping A, Fig. 12 ) if they could be obtained.
The simulation results presented here show that for the passively ABSORBED, reference COMPOUND (mol wt. ϭ 500, logP ϭ 3, pK a ϭ 7.4, base), higher levels of PGP did cause LUMINAL retention (Fig. 4) . The presence of more PGP for a fixed amount of CYP, in the absence of nonspecific binding, did increase exposure of drug to CYP, as measured by ER (Figs. 6B, 8B, and 11C ), but total METABOLISM diminished (Figs. 6A, 8A , and 11B); it did not increase, as had been speculated in the literature. The primary effect of PGP was the increased LUMINAL retention and more COMPOUNDs exiting the INTESTINE (Figs. 7A and  11A ). The explanation for increased ER values is that when PGP levels were elevated, total METABOLITE levels were reduced, but so were levels of COMPOUNDs in S3, sufficiently so that calculated ER values actually increased relative to corresponding values when PGP levels were lower. Nonspecific binding amplified the effect, in part because of the increased levels of COMPOUNDs in S3 (Fig. 11C) .
No synergy was observed for the dose studied. Counterintuitively, the results in Figs. 9 and 10 and Table 3 showed that measurable CYP-PGP antagonism occurred. There may be circumstances when similar antagonism occurs between metabolic enzymes and transporters within the intestine. To date, however, there have been no reports of such antagonisms. The results of earlier simulations (Liu and Hunt, 2006) indicated that it might be interesting to explore in more detail the consequences of different placements of CYP within S3 relative to S2 and restricted orientation of CYP and, in particular, PGP. Differences are known to exist between the proximal-to-distal mRNA expression patterns along the human intestine of members of both ABC and SLC families of transporters (Englund et al., 2006) . ABSORPTION, METABOLISM, and LUMINAL retention of the reference COMPOUNDs were strikingly sensitive to changes in CYP-PGP patterns. Not surprising was that pattern b in Fig. 5 was most effective in limiting ABSORPTION because CYP and PGP levels were highest when LUMINAL levels of COMPOUNDs were also highest.
For the conditions studied, maximum amount ABSORBED was always less than 40%. That was because the S1-S2 interface was simulated as having the same area as the S4-S5 interface. Doing so does not impact the observations reported here because the relative amounts of CYP and PGP will stay the same when effective surface areas are changed. When greater absorption is needed per unit length, possibly as a consequence of simulating increased surface area, several simulation options are available, and they are being explored.
Using a steady-state equational model, Ito et al. (1999) showed that for their model, the fraction absorbed increased following inhibition of PGP for a dual CYP-PGP substrate. Furthermore, absorption in their model increased when PGP was inhibited; the effect was greater in the case of simulated intracellular binding. ISID simulations showed the same effects. Their model exhibited synergy, whereas we detected none, but then they explored a greater range of conditions and did so under steady-state conditions. Their continuous model abstracted away important details that occur at the S1-S2 and S2-S3 interfaces. They also abstracted away the discrete nature of CYP-COMPOUND and PGP-COMPOUND interactions. These abstractions effectively couple the effects of transport and metabolism within the variables of their partial differential equations. We observed CYP-PGP antagonism. Their model made no a priori allowance for that possibility. The differences in stated uses, assumptions, and in simulation results between the two Fig.  9 . The designations are as specified in Fig. 9 . A, box, interquintile region. Whiskers span the range of 20 values. The diamond shows the value of the expected amount ABSORBED, assuming PGP and CYP are both active but no interaction occurred (as in Fig. 9) . B, experiments were the same as in Fig. 9B ; simulated nonspecific binding is designated §.
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at ASPET Journals on October 29, 2017 dmd.aspetjournals.org Downloaded from models help illustrate some of the strengths and weakness of each class of models. By representing clearance measures at steady state, Ito et al. abstracted away mechanistic details occurring within spaces; they also abstracted away differences in the proximal-to-distal pattern of interacting components. However, by imposing those abstractions, Ito et al. were able to explore a far larger region of their model's parameter and behavior space than was done with the ISID, and they can make precise predictions. Because of the presence of mechanistic details, the simulation time needed for an ISID to reach steady state would be hours for the single processors we used. The ISID was developed, in part, to explore the consequences of changes in spatial and configuration changes. If that is not an intended model use, which was the case for Ito et al., then an equational model is the better choice. For additional contrasts between models of the ISID class and traditional equation-based models, see Hunt et al. (2006) . It is worth recalling that all models of biological systems are, by necessity, abstractions. Consequently, whenever the subject of those abstractions becomes important to the measured properties of the model, all models that have adopted them are at risk of being wrong.
Motivated by the goal of having the ISTD (Garmire et al., 2007 ) and its descendants become useful tools for predicting in vitro transport properties of compounds based only on their structure, ISTDs were designed to exhibit nine capabilities. Four of those capabilities merit recall: 1) "Flexibility: it must be relatively simple to increase or decrease detail to . . . change usage and assumptions, without requiring significant reengineering." 2) "Reusability: device components can be designed to be autonomous and thus can be easily reconfigured to represent different cell types, experimental conditions, and compounds, alone or in combination. It must be easy to simulate and analyze outcomes of several different in silico experiments in a fraction of the time (and at a fraction of the cost) required to complete the wet lab experiments." 3) "Adaptability: in addition to flexibility and reusability, the components must be constructed so that they can be adapted to function as components in physiologically based, intestine and whole organism models." Because the ISTD cited above and its components were designed to exhibit these capabilities, it was straightforward to create and verify an ISID with minimum re-engineering by reusing already validated ISTD components. The conductor in Fig. 1 was new. However, the S1 to S5 spaces, along with the tight junction components from the ISTD, were reused with only the minor modifications detailed under Materials and Methods. The COMPOUNDs used in ISTD experiments were also used in these ISID experiments. PGP and its enabling algorithms were simplified versions of the ISTD's dual substrate ENZYME. 4) The fourth capability addresses the hypothesized mappings in Fig. 12 : "observables in silico are designed to be consistent with in vitro observables. Doing so FIG. 11 . The influences of PGP, CYP, and nonspecific INTRACELLULAR binding on LUMEN retention, METABOLISM, and extraction ratio. The data were collected from the experiments in Fig. 9 . The designations are the same as in Figs. 9 and 10 . A, shown are the LUMEN retention profiles for the eight conditions. §, nonspecific INTRACEL-LULAR binding is present. B, profiles of cumulative, total METABOLITEs produced for the four conditions where CYP is fully active (P 1 ϭ P 2 ϭ 1). C, values of extraction ratio were calculated and plotted each minute for the same four conditions as in B. enables clear mappings between in vitro and in silico components and mechanisms." The ISID is mechanistically realistic in part because it too exhibits these capabilities. Using the ISID to achieve greater insight into plausible mechanisms of intestinal absorption facilitates thinking more deeply about the far more complex referent system. ISID components can easily evolve over time. That bodes well for ISID's future uses and heuristic value. An example of a future use would be combining it with the in silico liver (Yan et al., 2007) to gain deeper insight into the complexities of bioavailability and thereby be better positioned to improve bioavailability predictions with the available, limited data. The diagram illustrates relationships between ISID mechanisms and components and corresponding mechanisms and components in an intestine during drug absorption. To the extent that mappings A to C are realistic, the relationship between a compound's PCPs and specific compound transport events will have an ISID counterpart. Discovering plausible methods to make a quantitative mapping between a drug's PCP and PCP-sensitive ISID parameter values will allow prediction of COMPOUND-specific, PCP-sensitive ISID parameter values, given only a new COMPOUND's PCP. ISID simulations using those predicted parameter values stand as a prediction of the expected disposition behavior of that new compound.
